Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02739542 · ClinicalTrials.gov registry record · Phase 4
Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
NCT02739542 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 87 participants.
The verdict
NCT02739542, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this investigation is to systematically study the efficacy of Tecfidera in those individuals who possess incidental white matter anomalies within the brain following a MRI study that is performed for a reason other than for the evaluation of MS (multiple sclerosis).
Interventions
- DRUG Placebo
- DRUG Tecfidera
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2016-03-19 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02739542
The ClinicalTrials.gov registry entry for NCT02739542 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02739542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02739542 about?
NCT02739542 is a clinical study titled "Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)". The purpose of this investigation is to systematically study the efficacy of Tecfidera in those individuals who possess incidental white matter anomalies within the brain following a MRI study that is performed for a reason other than for the evaluation of MS (multiple sclerosis).
What is the current status of trial NCT02739542?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2016-03-19. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02739542?
The interventions under investigation include: Placebo (DRUG), Tecfidera (DRUG).
Who is sponsoring clinical trial NCT02739542?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.